Miist, founded by a 25-year-old, wants people to vape their way out of smoking addiction and migraines | TechCrunch

Dalton Signor, concerned about smoking's impact on his family, founded Miist Therapeutics to create a quick-acting inhaler for addiction treatment. Traditional smoking cessation products take too long to act, leading to relapse, prompting his innovation of an inhaler that delivers medication directly to the lungs for rapid absorption. Miist has demonstrated significant efficacy, as evidenced by a Phase I trial where users reported a 92% reduction in cravings within two minutes. The company secured $7 million in seed funding, indicating strong investor confidence in its disruptive approach.

"They take about 30 minutes to provide relief, but the average person relapses in 11 minutes," he told TechCrunch.

"It's game-changing," Bilmoria said.

Read at TechCrunch